Skip to content
Open access

Engineering editopes through programmable RNA editing toward tumor neoantigen generation.

Aug 2026 · EMBO Journal · 0 citations · 60 references
Medicine

TL;DR

Short Precise-Encodable ADAR Recruiting (SPEAR) gRNAs are developed that harness endogenous ADAR1 to direct precise adenosine-to-inosine (A-to-I) editing at selected transcript sites and demonstrate the generation of immunogenic neoepitopes through RNA editing at the transcript level, termed editopes.

Abstract

Neoepitope-based therapies hold great promise for cancer immunotherapy because they target tumor-specific mutations and elicit potent anti-tumor T-cell responses. However, their clinical implementation remains limited by the complexity of neoepitope discovery and uncertainty regarding presentation by tumor cells. A potential alternative is the generation of immunogenic neoepitopes directly within cancer cells through programmable RNA editing. Here, we develop Short Precise-Encodable ADAR Recruiting (SPEAR) gRNAs that harness endogenous ADAR1 to direct precise adenosine-to-inosine (A-to-I) editing at selected transcript sites. Using these gRNAs, we demonstrate the generation of immunogenic neoepitopes through RNA editing at the transcript level, termed editopes. In a proof-of-concept model based on the melanoma antigen MART-1, SPEAR-mediated RNA editing restored antigen-specific T cell recognition and enabled tumor control in vivo. Finally, we developed a computational pipeline to identify candidate tumor-selective neoepitopes across multiple cancer types amenable to guided RNA editing. Our findings establish programmable RNA editing as a strategy for engineering immunogenic editopes and provide a framework for neoepitope-directed cancer immunotherapy.

Read PDF

Similar papers

Review Aug 2026

Mechanism of neoantigen generation and advances in neoantigen-based immunotherapies in colorectal cancer

This review outlines the molecular mechanisms driving neoantigen generation in CRC, including frameshift mutations, single-nucleotide variants, alternative RNA splicing, and circular RNA-derived epitopes, and evaluates neoantigen-directed therapeutic platforms, encompassing personalized neoantigen vaccines and adoptive...

Na Wang, Yi-Meng Xia, Ping Wang et al. · 0 citations
Review Open access Aug 2026

Neoantigen cancer vaccines in the mRNA Era: antigen selection, platform engineering, and clinical translation.

The strongest current signal supports use in adjuvant, perioperative, and minimal residual disease settings, usually in combination with checkpoint blockade or other immune-modifying strategies, usually in combination with checkpoint blockade or other immune-modifying strategies.

Minglu Ge, Ning Wu · 1 citation
Open access Jul 2026

A Singular Base Editing Platform for Polyfunctional Multiplex Engineering of Immune Cells.

This efficient engineering process of Iterative Nicking for Synchronous Engineered Reprogramming of T cells (INSERT) establishes a safe, simplified platform for advanced therapeutic CAR T engineering.

Joseph G. Skeate, Nicholas J. Slipek, Walker S. Lahr et al. · 0 citations
Review Open access Jul 2026

Editing around the target: epitope engineering to protect stem cell grafts

Collectively, epitope engineering of hematopoietic stem cells represents a versatile platform to expand the therapeutic window of precision immunotherapies and may enable safer, more effective combinatorial treatment strategies for both nonmalignant and malignant hematologic conditions.

Joanne Baek, G. Casirati, Pietro Genovese et al. · 0 citations
Review Open access Aug 2026

Targeting splicing-derived neoantigens for precision cancer immunotherapy

This review integrates current understanding of the biological origins, immunological barriers, target classes of splicing neoantigens, and the technologies that enable their advancement in cancer immunotherapy to produce two major classes of immunotherapeutic targets.

Mu-Tian Tang, H. L. Grimes, Nathan Salomonis · 0 citations

We use cookies to run the site and, with your consent, for analytics and to show ads. See our Cookie Policy.